By Aidan Sowa, CEO and Founder, Frontier Industries | October 2026
Telehealth was a contingency plan until the spring of 2020, when it became the front door of medicine in a matter of weeks. The companies that survived the surge now face a colder problem: the emergency ended, the waivers are expiring in pieces, and the public has learned to love the convenience while doubting the privacy. This guide compares agency types against the telehealth workload as it actually is: policy storytelling, trust repair, clinician credibility and growth that does not outrun the law. It uses federal usage data and enforcement records. Your product is a consultation. Your reputation is a data policy. Choose accordingly.
Key numbers for this decision:
- 37.0 percent: adults who used telemedicine in the previous twelve months in 2021, the baseline the post emergency market settled from (CDC National Center for Health Statistics, 2022)
- 42.0 percent: usage among women, against 31.7 percent among men (CDC NCHS, 2022)
- 43.3 percent: usage among adults aged 65 and over, the highest of any age group (CDC NCHS, 2022)
I Discrimen
You sell access, and you are judged on what happens to the data
That is the distinction consumer health buyers now make instinctively. The visit is the easy part: a screen, a clinician, a prescription where appropriate. The judgement happens afterwards and elsewhere, in the privacy policy nobody reads until a headline teaches them to, in the tracker list on your intake pages, in the enforcement release with a competitor name in it. An agency for a telehealth company must therefore be as literate in data practice as in storytelling, because in this category the two are the same document.
Consumer technology agencies miss this entirely. They market health apps like travel apps, optimise intake funnels for conversion, and treat consent as a legal footer. Healthcare firms can miss the other half, writing communications so guarded that a genuinely useful service sounds like a compliance seminar. The firm you need holds the tension in one voice: warm about access, exact about data, and never confused about which sentence a regulator will quote.
Convenience is the advert. Confidentiality is the brand. A company that inverts them eventually gets a very public lesson in the difference.
Test finalists with your own tracking stack. Ask them to walk your intake journey and name the privacy questions a journalist would ask. You will learn in ten minutes whether you are hiring communications counsel or a content vendor.
II Machina
Policy is your weather, and it changes by state and by session
No other health category in this series lives this exposed to rulemaking. Reimbursement parity, interstate licensure, prescribing rules for controlled substances, originating site and modality restrictions: each can expand or contract your market by statute, and each is argued in public, in statehouses and in the press. Your agency is therefore partly a public affairs firm whether you planned it or not. It must translate a technical rule change into language patients, clinicians and legislators each understand, and it must do it before opponents frame the change for you.
The consumer mechanism runs in parallel. CDC data shows telemedicine use in 2021 reached 37.0 percent of adults, rising with age to 43.3 percent among those 65 and over (CDC NCHS, 2022). Your heaviest users are not digital natives showing off; they are older patients managing chronic conditions who value the saved journey. Communications pitched only at young urban convenience seekers miss the demographic that actually fills your schedule and votes on your policy questions.
An agency worth its retainer runs both mechanisms as one programme: policy storytelling that keeps your market legal, and patient storytelling that keeps it full, with the data story, what you collect, what you never collect, stated plainly across both.
III Exemplum
The GoodRx enforcement taught the whole category what a privacy claim costs
In 2023 the Federal Trade Commission fined GoodRx 1.5 million dollars and banned it from sharing health data for advertising, in the first action under the Health Breach Notification Rule, after finding the company had shared users health information with advertising platforms despite promising the opposite (FTC, 2023). Read that case as a communications document. The violation was technical, but the injury was literary: the company public promises and its data practice described two different businesses.
Every telehealth company now operates in the shadow of that gap. Your marketing says discreet, private, secure. Your tag manager says something more complicated. Journalists and regulators have learned to compare the two, and plaintiffs lawyers have learned to read both. An agency that does not audit the distance between your claims and your configuration is not protecting your reputation; it is typesetting your enforcement release.
The positive version of the lesson matters too. Companies that publish plain data practices, minimise collection and can explain their stack in one honest page have turned the category anxiety into their strongest differentiator. In a market where trust is the scarce resource, audited modesty outsells loud assurance.
Notice also who told the story. The enforcement was covered as a business scandal, not a technical footnote, because the FTC framed it as a broken promise to consumers. That framing is now the default lens for the category: any telehealth company whose marketing promises discretion while its growth stack whispers data to advertising platforms will be written about as a hypocrite first and a health provider second. Your agency should assume that lens in every planning meeting and test each campaign against the headline it would generate if the underlying data flows were printed beside it. Campaigns that survive that test are the only ones worth running.
IV Damnum
What fails first is not demand, it is permission
Telehealth demand does not collapse. Permission does: an app store policy change, a payer narrowing its panel, a state board tightening prescribing, an employer benefits team spooked by a privacy headline. Each is a communications event as much as a commercial one, decided by how much organised goodwill and credible explanation you can deploy in a fortnight. Companies that treat public affairs as a launch accessory discover its real price during the first contested renewal.
Clinician supply is the second front. Virtual care competes for licensed clinicians across state lines, and clinicians choose platforms whose public reputation they are willing to be named by. A company known for careful prescribing and clinician respect recruits in a different pool from a company known for volume at any cost. Your employer brand and your consumer brand are the same brand in this category; pretending otherwise just means managing it badly twice.
Then there is the equity exposure. Usage data shows telemedicine adoption varies by income, education and rurality (CDC NCHS, 2022). Companies that celebrate access while their service quietly excludes the patients with the worst connectivity will eventually be profiled for the gap. The communications defence is not better adjectives. It is a product and policy story honest enough to survive the profile.
Investors read all of this too. Telehealth valuations now price regulatory durability and trust alongside growth, because acquirers and public markets have watched privacy and prescribing stories erase years of brand building in a quarter. A communications programme that documents its claims, its policy positions and its clinical standards is quietly building the diligence file your next financing will be judged on. Founders tend to discover this in the data room. It is cheaper to discover it in the agency brief.
V Genus
The agency field for telehealth, sorted by what each actually sells
| Agency type | Genuine strength | Blind spot to price in |
|---|---|---|
| Health policy and public affairs firm | Rulemaking fluency, coalition building, payer and legislator credibility | Consumer growth and product storytelling pace |
| Healthcare specialist PR firm | Clinical credibility, crisis steadiness, data ethics instinct | Policy detail and consumer funnel craft |
| Consumer technology agency | Launch energy, app store and product narrative | Privacy and prescribing nuance, sometimes fatally |
| Digital growth agency | Acquisition systems, content engines, testing discipline | Will optimise any claim that converts until stopped |
| Integrated health and tech firm | Both registers in one team, if genuinely staffed that way | The integrated promise often exceeds the integrated roster |
The winning configuration for most platforms is a policy and healthcare core with growth skills attached under governance, not the reverse. Growth can be throttled in a week. Credibility, once spent on a claim your data practice contradicts, takes years to refinance.
Interview accordingly: spend half the pitch on the rule change scenario. A federal prescribing rule tightens in ninety days, a trade reporter is writing this week, and your clinical leadership disagrees about the response. Watch who in the room reaches for facts, coalitions and clinician voices, and who reaches for adjectives.
VI Regio
Segment by licence map and by condition, not by download numbers
Your true market is a map of permissions: the states where your clinicians are licensed, the conditions your protocols cover, the payers whose panels you sit on. Communications that ignore the map generate demand you cannot legally serve, which in health care is not a funnel problem but a trust bonfire. Ask agencies how they geo discipline campaigns and what they do with out of footprint demand. The grown up answer involves waitlists, content value and policy advocacy aimed at the map itself.
Condition segments differ in kind. Mental health telehealth carries the confidentiality sensitivity described in the companion guide for mental health providers. Dermatology and primary care carry image and continuity questions. Weight management and other high demand categories carry prescribing scrutiny that can turn a marketing success into a regulatory case study in a single quarter. Your agency must staff and message each segment at its own risk temperature, not at the average.
Employer and payer channels form a third segment with a wholly different dialect: outcomes, utilisation, member satisfaction and auditability. One integrated narrative will not survive contact with all three audiences. Require the plan to show its seams.
VII Occasio
The opening: older patients trust it, use it most, and are served worst by most marketing
The usage data holds a positioning gift. Adults over 65 used telemedicine at the highest rate of any age group, 43.3 percent in 2021 (CDC NCHS, 2022), yet telehealth marketing overwhelmingly performs youth: apps as lifestyle, care as convenience content. A company that speaks to its actual heaviest users with respect, larger promises kept small, human help visible, clinicians introduced by name and specialty, takes ground competitors are abandoning while chasing a demographic that churns.
The equaliser underneath is trust portability. A telehealth brand that becomes the safe pair of hands for a family older generation gets handed down: adult children managing parents care become users, then advocates, then the workforce audience your employer channel needs. Reputation compounds down the generations in this category in a way app metrics never capture.
Agencies that see this will propose a clinician bench of mature, credible specialists and a content programme built on chronic care usefulness. Agencies that do not will propose an influencer. Choose the bench.
The bench pays for itself in an unexpected currency: correction resilience. When a telehealth company with visible, trusted clinicians makes a genuine mistake, a service outage, a billing error, a policy misunderstanding, its public starts from belief rather than suspicion. Companies without faces get no such grace; their mistakes are read as character. In a category where operational incidents are guaranteed and regulatory weather is permanent, that starting position is the difference between a bad week and a bad year, and it is built entirely in peacetime.
VIII Consilium
A scorecard weighted for a policy exposed business
| Criterion | Weight | Evidence to demand |
|---|---|---|
| Privacy claim auditing | 25 percent | A worked review of claims against data practice |
| Policy and public affairs depth | 25 percent | Staff who have run a rulemaking or parity campaign |
| Clinical credibility | 20 percent | Clinician spokesperson system and prescribing ethics fluency |
| Segment discipline | 15 percent | Separate plans by licence map, condition and channel |
| Crisis readiness | 10 percent | Response plan for a data incident or prescribing story |
| Growth craft | 5 percent | Present, governed, and clearly subordinate |
Contract for a claims register: every public claim about privacy, access and outcomes logged with its evidence and owner, reviewed quarterly. Add a rule that growth experiments touching health claims require communications sign off. These two clauses prevent most of the category famous disasters, and the firms that welcome them are telling you who they are.
The public relations services page describes one governance first model, and the full sector set is in the resources library.
Frequently asked questions
How do we talk about privacy without inviting scrutiny we cannot survive?
By claiming less and proving more. Publish your data practice in plain language, name what you do not do, minimise trackers on health pages, and let your agency audit the claims against the configuration every quarter. Scrutiny is survivable when the documents match. It is only fatal when the adjectives outran the architecture.
Should we engage on telehealth policy publicly or stay quiet?
Engage, precisely and early. Rule changes decide your market, and the record is written by whoever shows up with credible patient and clinician stories. Quiet companies get framed by louder interests, sometimes competitors, sometimes sceptics of the whole model. A public affairs capability is not optional equipment in this category.
How do we recruit clinicians with communications?
Show them the practice they would be joining: careful protocols, named clinical leadership, honest prescribing standards, and peers who speak publicly with pride. Clinicians read your consumer marketing as a proxy for your clinical culture. Volume boasting repels exactly the licence holders you most want.
What is our biggest reputational risk?
The gap between the privacy promise and the data plumbing, followed closely by prescribing corners cut under growth pressure. Both risks are manageable with audits and governance, and both are catastrophic when discovered by a regulator or a reporter before they are discovered by you. Commission the audit before the campaign, every time.
Can one agency cover consumers, employers and policymakers?
One firm can, if it staffs three registers and admits they are different jobs. Test for it by asking for the same announcement written three ways in the pitch process: a patient post, an employer brief and a policymaker one pager. Firms that produce three genuinely different documents understand your market. Firms that produce one document with three covers do not.
How fast can trust building show commercial results?
Employer and payer cycles are slow, two to four quarters. Consumer trust signals, conversion on high intent pages, clinician application quality and completion rates, move within a quarter when the claims get cleaner and the clinician bench gets visible. Judge the programme on a blended dashboard or you will strangle the policy work that protects everything else.
How this guide was built
This guide is based on CDC National Center for Health Statistics telemedicine research, Federal Trade Commission enforcement records, and KFF telehealth policy analysis, listed below. Telehealth law is a moving patchwork of federal and state rules, and several pandemic era flexibilities remain under active debate, so positions stated here are a framework for choosing counsel and communications partners, not a statement of current law in any state.
IX Incipe
Where Frontier Industries fits
Frontier Industries runs telehealth accounts governance first: claims audited against data practice, policy storytelling staffed by people who have sat in the hearings, and growth kept on a documented leash. The team background is on the about page.
If your platform is choosing now, bring your privacy page and your licence map to one conversation: start an industry campaign enquiry or call 401-219-4207.
Sources
1. CDC National Center for Health Statistics, Telemedicine Use Among Adults: United States, 2021, Data Brief 445. https://www.cdc.gov/nchs/products/databriefs/db445.htm 2. CDC, Telemedicine use data brief full text, National Health Interview Survey 2021. https://stacks.cdc.gov/view/cdc/121435 3. Federal Trade Commission, FTC action against GoodRx for sharing health data, Health Breach Notification Rule enforcement, 2023. https://www.ftc.gov/news-events/news/press-releases/2023/02/ftc-enforcement-action-ban-goodrx-sharing-consumers-sensitive-health-data-advertising-purposes-will 4. KFF, Telehealth policy and usage analysis. https://www.kff.org/telehealth/ 5. HHS Office for Civil Rights, HIPAA and telehealth guidance. https://www.hhs.gov/hipaa/index.html 6. KFF, Health information and trust polling, including confidence in providers and agencies, 2025. https://www.kff.org/health-information-trust/new-kff-poll-shows-public-divided-when-it-comes-to-trusting-federal-health-agencies-for-reliable-information/ 7. American Telemedicine Association, policy and practice resources. https://www.americantelemed.org/ 8. CDC, Telehealth and virtual care resources. https://www.cdc.gov/telehealth/index.html 9. Edelman, Trust Barometer, technology and health findings. https://www.edelman.com/trust-barometer 10. Press Ganey, Virtual care patient experience research. https://www.pressganey.com/resources/